Wolverine Stack

Category	Stacks
Also known as	Wolverine, BPC TB Recovery
Last updated	2026-04-14
Reading time	3 min read
Tags	stackhealingrecoverysoft-tissue

Overview

The Wolverine Stack is the canonical two-peptide recovery combination, pairing BPC-157 with TB-500. Named for the comic book character associated with rapid healing, it is one of the most widely referenced peptide stacks in the connective-tissue and tendon research literature.

The pairing is conceptually simple: combine a peptide investigated for angiogenesis and growth-factor receptor upregulation with a peptide investigated for cellular migration and actin sequestration. Together, the two cover overlapping but distinct phases of the wound healing cascade, providing a more complete signal set than either compound alone.

The Wolverine Stack is the foundation upon which broader formulations like the GLOW Stack and KLOW Stack are built, and it appears in many compounded research products including those from WMP. It is most often discussed in the context of tendon, ligament, and joint injury models.

Compounds in This Stack

BPC-157 — Body Protection Compound, a 15-amino-acid stable gastric peptide studied for soft-tissue repair, tendon-to-bone healing, and gut research.
TB-500 — Synthetic fragment of Thymosin Beta-4, studied for systemic actin regulation, cell motility, and ischemic recovery.

Rationale

The mechanistic complementarity in Wolverine is straightforward. BPC-157 is studied for upregulation of VEGF receptor 2 (VEGFR2), nitric oxide signaling, and growth-hormone receptor expression in tendon — supporting the angiogenic and proliferative arms of repair. TB-500 sequesters G-actin monomers, modulates cytoskeletal dynamics, and is investigated for facilitating cell migration into damaged tissue.

Combined, the two are conceptualized as a "build the road, then drive the cells" pairing — BPC-157 prepares vasculature and growth factor receptivity, TB-500 mobilizes the cellular workforce. The two peptides also have non-overlapping receptor profiles, reducing concerns about competitive binding or saturation.

Research Context

Component	Primary Research Focus
BPC-157	Tendon-to-bone healing, gastric mucosa, angiogenesis, nerve repair
TB-500	Cardiac and skeletal muscle ischemia, hair follicle migration, corneal healing

Most BPC-157 and TB-500 data is preclinical, with animal models showing improved repair endpoints versus saline controls. Combination-specific data is limited, but the pairing is widely documented in research-product protocols.

Typical Research Parameters

The Wolverine Stack is generally studied in observation windows of four to eight weeks. Researchers often co-administer the two peptides subcutaneously, sometimes at the site of interest for localized models or systemically for whole-body recovery work. Because TB-500 has a longer functional half-life associated with its actin-binding profile, dosing intervals for the two compounds frequently differ, with TB-500 administered less often than BPC-157.

Considerations

Both peptides are considered to have favorable preclinical safety profiles, but neither is approved for clinical use. Researchers note that aggressive recovery support during early-stage injury models can theoretically mask warning signs of structural instability, which is a methodological consideration rather than a pharmacological one. The Wolverine Stack does not address inflammation specifically — protocols seeking that arm typically expand to the KLOW Stack or pair Wolverine with KPV.